Additional file 1: of Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors

Figure S1. MRI images, histology and representative flow cytometry plots of normal or tumor-bearing lungs before and after erlotinib. (A) Coronal images of CCSPrtTA; TetO-EGFRL858R mouse lungs before (left panel) and after (right panel) treatment with erlotinib. (B) Hematoxylin and eosin (H&E) stain of lungs from control (normal) and tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks. Bar: 50 μm. Absolute number of (C) CD4 and (D) CD8 T cells normalized to weight of lungs of control (normal) and tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks. Representative FACS plot showing percentage of (E) FoxP3+ and FoxP3- CD4+ T cells (F) PD1+ FoxP3+ T cells. (G) Immunofluorescence (IF) stain of lung epithelial cells (green), CD3 T cells (red) and FoxP3 Tregs (Cyan). Nuclei were counterstained with Dapi (blue) (H) Quantification of FoxP3+ CD3 T cells in lung tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks stained by IF. Data are shown as mean ± SD and * is P